Pn-MAPS30plus
Sponsors
GlaxoSmithKline
Conditions
Pneumonia, Bacterial
Phase 1
A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
CompletedNCT07105722
Start: 2025-08-12End: 2026-05-06Updated: 2026-06-05
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose
Not yet recruitingNCT07406334
Start: 2026-05-15End: 2027-02-22Target: 45Updated: 2026-02-12
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
Not yet recruitingNCT07406347
Start: 2027-01-25End: 2028-10-18Target: 60Updated: 2026-07-16
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
Active, not recruitingNCT07428759
Start: 2026-03-10End: 2026-12-09Updated: 2026-05-27